Each capsule contains:
Piroxicam 10 mg
Osteoarthritis, Rheumatoid Arthritis.
Dosage and administration:
Usual: 20mg qd; may divide daily dose
Adjust dose and frequency after observing response to initial therapy
Use lowest effective dose for shortest duration consistent with individual patient treatment goals.
Note: take with or just after food, or a meal.
Pregnancy & Breastfeeding:
Category C (1st and 2nd trimester) and D (3rd trimester), caution in nursing.
History of asthma, urticaria, or other allergic-type reactions with ASA or other NSAIDs.
Treatment of perioperative pain in the setting of CABG surgery.
Precaution & warnings:
Use lowest effective dose for the shortest duration possible.
May cause hypertension or worsen preexisting hypertension; monitor BP closely.
Fluid retention and edema reported; caution with fluid retention, hypertension, or HF.
Extreme caution with history of ulcer disease or GI bleeding, or risk factors for GI bleeding (eg, longer duration of NSAID therapy, older age, poor general health status); monitor for GI ulceration/bleeding, and discontinue if serious GI adverse event occurs.
Renal injury reported with long-term use; increased risk with renal/hepatic impairment, hypovolemia, HF, salt depletion, and in elderly.
Discontinue if signs and symptoms consistent with renal disease develop.
Anaphylactoid reactions may occur.
May cause serious skin adverse events (eg, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis); discontinue at 1st appearance of skin rash/hypersensitivity.
Anemia reported; monitor Hgb/Hct if anemia develops.
May cause elevations of LFTs or severe hepatic reactions; discontinue if liver disease or systemic manifestations occur, or if abnormal LFTs persist/worsen.
May inhibit platelet aggregation and prolong bleeding time; monitor patients with coagulation disorders.
Monitor CBC and chemistry profile periodically with long-term treatment.
May delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in women; consider withdrawal of therapy in women who have difficulties conceiving or who are undergoing investigation of infertility.
Caution in debilitated and poor CYP2C9 metabolizers.
CV thrombotic events, MI, stroke, GI bleeding, GI ulceration, stomach/intestinal perforation, dizziness, headache, pruritus, rash, tinnitus, anorexia, abdominal pain, diarrhea.
- Monitor for a change in dosage requirements when administered with other highly protein bound drugs.
- Not recommended wth ASA; potential for increased adverse effects.
- May enhance methotrexate toxicity; use caution when coadministered.
- May diminish the antihypertensive effect of ACE inhibitors.
- May reduce the natriuretic effect of thiazide and loop (eg, furosemide) diuretics. Increased risk of renal toxicity with diuretics and ACE inhibitors; monitor renal function.
May elevate lithium levels; monitor for signs of lithium toxicity.
Increased risk of GI bleeding with oral corticosteroids or anticoagulants (eg, warfarin), smoking, and alcohol.
- Monitor patients receiving anticoagulants.
- Store below 30°C, protect from heat.
- Keep out of reach of children.